Huperzine A: An acetylcholinesterase inhibitor with high pharmacological potential;L'huperzine A: Un inhibiteur de l'acetylcholinesterase a fort potentiel pharmacologique

Annales Pharmaceutiques Francaises

Volumn 57, Issue 5, 1999, Pages 363-373

  Pilotaz, F ^a   Masson, P ^a  

^a CENTRE DE RECHERCHES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINESTERASE; CHOLINESTERASE INHIBITOR; HUPERZINE A; NEUROPROTECTIVE AGENT; NOOTROPIC AGENT; ORGANOPHOSPHORUS COMPOUND;

ALZHEIMER DISEASE; COGNITION; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME INHIBITION; HUMAN; INTOXICATION; NONHUMAN; REVIEW;

ANIMALS; CHOLINESTERASE INHIBITORS; HUMANS; NEUROPROTECTIVE AGENTS; SESQUITERPENES;

EID: 0032863808     PISSN: 00034509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Unni LK. Recently developed cholinesterase inhibitors for the treatment of Alzheimer's disease, CNS Drugs, 1998, 10, 6, 447-60.
2. Inestrosa NC, Alvarez A, Perez CA, Moreno RD, Vicente M, Linker C, Casanueva OI, Soto C, Garrido J. Acetylcholinesterase accelerates assembly of amyloid - β peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme., Neuron, 1996, 16: 881-91.
3. Inestrosa NC, Alarcon R Molecular interations of acetyl-cholinesterase with senile plaques, J Physiol (Paris), 1998, 92: 341-4.
4. Tang XC. Huperzine A (Shuangyiping): a promising drug for Alzheimer's disease, Acta Pharmacol Sin, 1996, 17, 6: 481-4.
5. Patocka J. Huperzine A an interesting anticholinesterase compound from the Chinese herbal medicine, Acta Medica, 1998, 41: 155-7.
6. Kozikowski AP, Tuckmantel W. Chemistry, pharmacology and clinical eflicacy of the Chinese nootropic agent huperzine A, Acc Chem Res, 1999, sous presse.
7. Guillaume G. La médecine traditionnelle chinoise. Historique. Apports et potentialités Éditions techniques, Encycl Med Nat (Paris), Phytothérapie, Aromathérapie, A-3-1, 1991, 28 pages.
8. Zhu DY, Bai DL, Tang XC. Recent studies on traditional Chinese Medicinal plants., Drug Develop Res, 1996, 39: 147-57.
9. Bruneton J. Pharmacognosie Deuxième édition. Tec & Doc Lavoisier, Paris, 1993 : 690.
10. Wichtl M. Herbal drugs and phytopharmaceuticals., CRC Press, 1994: 309-10.
11. Liu JS, Huang MF. The alkaloids huperzines C and D and huperzinine from Lycopodiastrum casuarinoides, Phytochem, 1994, 37, 6: 1759-61.
12. Xia Y, Kozikowski AP. A practical synthesis of the Chinese nootropic agent huperzine A: A possible lead in the treatment of Alzheimer's disease, J Amer Chem Soc, 1989, 111, 11: 4116.
13. Kozikowski AP, Xia Y, Reddy ER, Tuckmantel W, Hanin I, Tang XC. Synthesis of huperzine A and its analogues and their anticholinesterase activity., J Org Chem, 1991, 56, 15, 4633-45.
14. Muszynski. J. The alkaloids of clubmosses., Quart J Pharm Pharmacol, 1948, 21: 34-8.
15. Ayer WA, Browne LM, Orszanska H, Valenta Z, LIU JS. Alkaloids of Lycopodium selago: on the identity of selagine with huperzine A and the structure of a related alkaloid., Can J Chem, 1989, 67: 1538-40.
16. e ́dition, Merck & Co. Inc, Rahway, 1989.
17. Liu JS, Zhu YL, Yu CM. The structures of huperzine A and B, two new alkaloids exhibiting marked anticholinesterase activity., Can J Chem, 1986, 64, 4; 837-9.
18. Ashani Y, Peggins JO, Doctor BP. Mechanism of inhibition of cholmesterases by huperzine A., Biochem. Biophys Res Communic. 1992, 184, 2: 719-26.
19. Wang YE, Yue DX, Tang XC. Anticholinesterase activity of huperzine A., Acta Pharmacol Sin, 1986, 7, 2: 110-3. In. Drugs of the future, 1987, 12, 6: 531.
20. Wang YE, Yue DX, Tang XC. Anticholinesterase activity of huperzine A., Acta Pharmacol Sin, 1986, 7, 2: 110-3. In. Drugs of the future, 1987, 12, 6: 531.
21. Hao XY, Gong ZH, Qin BY. Effects of huperzine A on cholinesterase isoenzymes in plasma of mice and dogs., Acta Pharmacol Sin, 1988, 9, 4 312-6. In: Drugs of the future, 1989, 14, 6: 575.
22. Hao XY, Gong ZH, Qin BY. Effects of huperzine A on cholinesterase isoenzymes in plasma of mice and dogs., Acta Pharmacol Sin, 1988, 9, 4 312-6. In: Drugs of the future, 1989, 14, 6: 575.
23. Cheng DH, Ren H, Tang XC. Huperzine A a novel acetylcholinesterase inhibitor., Neurorepon, 1996, 8, 1 97-101.
24. Saxena A, Qian N, Kovach I.M, Kozikowski AP, Pang YP, Vellom DC, Radic Z, Quinn D, Taylor P, Doctor BP. Iden- tification of amino acid residues involved in the binding of Huperzine A to cholmesterases, Prot Sci 1994, 3 1770-8.
25. Raves ML, Harel M, Pang YP, Silman I, Kozikovsk AP, Sussman JL. Structure of the acetylcholinestcrase complexed with the nootropic alkaloid, (-)-huperzine A., Nat Struct Biol, 1997, 4, 1: 57-63.
26. Ashani Y, Grunwald J, Kronman C, Velan B, Shafferman A. Role of tyrosine 337 in the binding of huperzine A to the active site of human acetylcholinesterase, Mol Pharmacol, 1994, 45: 555-60.
27. Saxena A, Redman AMG, Jiang X, Lockridge O, Doctor BP. Differences in active site gorge dimensions of cholinesterases revealed by binding of inhibitors to human cholinesterase, Biochemistry, 1997, 36: 14642-51.
28. Sussman JL, Harel M, Frolow F, Oefner C, Goldman A, Toker L, Silman I. Atomic structure fo acetylcholinesterase from Torpedo californica: A prototypic acetylcholine-binding protein, Science. 1991, 253: 872-9.
29. Skolnick AA. Old Chinese herbal medicine used for fever yields possible new Alzheimer disease therapy., JAMA, 1997, 277, 10:776.
30. Kozikowski AP, Ding Q, Saxena A, Doctor BP. Synthesis of (±)-10, 10-dimethylhuperzine A A huperzine Analogue possessing a slower enzyme off rate, Bioorg Med Chem Lett, 1996, 6, 3: 259-69.
31. Badia A, Banos JE, Camps P, Contreras J, Görbig DM, Munoz-Torrero D, Simon M, Vivas NM. Synthesis and Evaluation of Tacrine-Huperzine A Hybrids as Acetylcholinesterase Inhibitors of Potential Interest for the Treatment of Alzheimer's Disease. Bioorg Med Chem, 1998, 6: 427-49.
32. Fanxing Z, Hualiang J, Xican T, Kaixian C, Ruyun J. Synthesis and acetylcholinesterase inhibitory activity of (±) 14 fluorohuperzine A, Bioorg Med Chem Lett, 1998, 8: 1661-4.
33. Tang XC, De Sarno P, Sugaya K, Giacobini E. Effect of huperzine A, a new cholinesterase inhibitor, on the central cholinergic system of the rat., J Neurosci Res, 1989, 24, 2: 276-85.
34. Hanin I, Tang XC, Kindel G, Xia Y, Kozikowski AP. Synthetic and natural huperzine A: Comparison of their effects on rat CNS neurotransmitters in vivo., Pharmacologist, 1990, 32, 3. Abst 100.
35. Me Kinney M, Miller JH, Yamada F, Tuckmantel W, Kozikowski AP. Potencies and stereoselecivities of enantiomers of huperzine A for inhibition of rat conical acetylcholinebterase. Eur J Pharmacol, 1991, 203, 2: 303-5.
36. Laganiere S, Corey J, Tang XC, Wulfen E, Hanin I. Acute and chronic studies with the anticholinesterase huperzine A Effect on central nervous system cholnergic parameters., Neuropharmacol 1991, 31, 7, 763-8.
37. Zhu XD, Giacobini E. Second generation choiinesterase inhibitors: effect of (L)-hupemne A. on cortical biogenic amines., J Neurosci Res. 1995, 41 6 828-35.
38. Zenghong T, Meiying W. Miuagenicity and comunagemcity of three nootropics: huperzine A, antracetam and piracetam., New drugs Clin Rem, 1990, 9, 2 65-8.
39. Wang YE, Feng J, Lu WH, Tang XC. Pharmacokinetics of huperzine A in rats and mice., Acta Pharmacol Sin, 1988, 9: 193-196. In: Drugs of the future, 1989, 14, 6 575.
40. Wang YE, Feng J, Lu WH, Tang XC. Pharmacokinetics of huperzine A in rats and mice., Acta Pharmacol Sin, 1988, 9: 193-196. In: Drugs of the future, 1989, 14, 6 575.
41. Zhu XD, Tang XC, Facilitatory effects of huperzine A and B on learning and memory of spatial discrimination in mice., Yaoxue Xuebao, 1987, 22, 11. 812-7. int. Drugs of the future, 1988, 13, 6: 575.
42. Zhu XD, Tang XC, Facilitatory effects of huperzine A and B on learning and memory of spatial discrimination in mice., Yaoxue Xuebao, 1987, 22, 11. 812-7. int. Drugs of the future, 1988, 13, 6: 575.
43. Zhu XD, Tang XC. Improvement of impaired memory in mice by huperzine A and huperzine B., Acta Pharmatol Sin, 1988, 9, 6, 492-497. In: Drugs of the future, 1989, 14 6 575.
44. Zhu XD, Tang XC. Improvement of impaired memory in mice by huperzine A and huperzine B., Acta Pharmatol Sin, 1988, 9, 6, 492-497. In: Drugs of the future, 1989, 14 6 575.
45. Tang XC, Han YF, Chen XP, Zhu XD. Effects of huperzine A on learning and retrieval process of discrimination performance in rats., Acta Pharmacol Sin, 1986, 7. 6: 507-511. In: Drugs of the funture, 1987, 12, 6: 531.
46. Tang XC, Han YF, Chen XP, Zhu XD. Effects of huperzine A on learning and retrieval process of discrimination performance in rats., Acta Pharmacol Sin, 1986, 7. 6: 507-511. In: Drugs of the funture, 1987, 12, 6: 531.
47. Dong ZJ, Lo YL, Chan KY, Han YF. Comparative studies of huperzine A and tacrine on sccopolamine-induced amnesia of shuttle-box active avoidance in adult and aged rats., Soc Neurosci Abst, 1996, 22, 1. abst 147.11.
48. Xiong ZQ, Han YF, Tang XC. Huperzine A ameliorates the spatial working memory impairments induced by AF64A., Neuroreport, 1995, 6, 16: 2221-4.
49. Xiong ZQ, Cheng DH, Tang XC Effects of huperzine A on nucleus basalis magnocellularis lesion-induced spatial working memory deficit., Acta Pharmacol Sin, 1998, 19, 2: 128-32.
50. Wang T, Tang XC. Reversal of scopolamine-induced deficits in radial maze performance by (-)-huperzine A: comparison with E2020 and tacrine., Eur J Pharmacol, 1998, 349, 137-42.
51. Cheng DH, Tang XC. Comparative studies of Huperzine A, E2020, an Tacrine on behavior and cholinesterase activities, Pharmacol Biochem Behav, 1998, 60, 2: 377-86.
52. Ved HS, Koenig ML, Dave JR, Doctor BP. Huperzine A, a potential therapeutic agent for dementia, reduces cell death caused by glutamate., Neuroreport, 1997, 8, 4: 963-8.
53. Grunwald J, Raveh L, Doctor BP, Ashani Y. Huperzine A as a pretreatment candidate drug against nerve agent toxicity. Life Sci. 1994, 54, 14: 991-7.
54. S. Ashani Y, Grunwald J, Alkalai D, Cohen G, Raveh L. Studies with huperzine A, a new candidate in the research of prophylaxis against nerve agents., Medical Defense Bioscience Review, 1996, 1: 105-10.
55. Lallement G, Veyret J, Masqueliez C, Aubriot S, Burckhart MF, Baubichon D. Efficacity of huperzine A in preventing soman-induced seizures, neuropathological changes and lethality., Fundam Clin Pharmacol, 1997, 11: 387-94.
56. Qian BC, Wang M, Zhou ZF, Chen K, Zhou RR, Chen GS. Pharmacokinetics of huperzine A in six volunteers., Acta Pharmacol Sin, 1995, 16: 396-8.
57. Cheng YS, Lu CZ, Ying ZL, Ni WY, Zhang CL, Song CW. 128 cases of myasthenia gravis treated with huperzine A., New drugs Clin Rem, 1986, 5: 197-9.
58. Zhang S.L Therapeutics effects of huperzine A on the aged with memory. New Drugs Clin Rem, 1986, 5: 260-2.
59. Zhang RW, Tang XC, Han YY. Drug evaluation of huperzine A in the treatment of senile memory disorders. Acta Pharmacol Sin, 1991, 12, 3: 250-2.
60. Xu SS, Gao ZX, Weng Z. Efficacity of tablet huperzine A on memory, cognition and behavior in Alzheimer's disease., Acta Pharmacol Sin, 1995, 16, 5: 391-5.
61. Canal L, Imbimbo BP. Relationship between pharmacodynamic activity and cognitive effects of eptastigmine in Alzheimer patients, Clin Pharmacol Ther, 1996, 60: 218-28.
62. Williams BR. Metrifonate: A new agent for the treatment of Alzheimer's disease. Am J Health Syst, 1999, 56, 5:427-32.
63. Otoguro K, Kuno F, Omura S. Arisugacins, selective acetylcholinesterase inhibitors of microbial origin, Pharmacol Ther, 1997, 76, 7-3:45-54.
64. Schachter AS, Davis KL. Guidelines for the appropriate use of cholinesterase inhibitors in patients with Alzheimer's disease. CNS Drugs, 1999, 11: 281-8.
65. Sramek JJ, Cutler NR. Recent devolpments in the drug treatment of Alzheimer's disease. Drugs & Aging, 1999, 14: 359-73.